المؤلفون: Asnicar F., Leeming E. R., Dimidi E., Mazidi M., Franks P. W., Al Khatib H., Valdes A. M., Davies R., Bakker E., Francis L., Chan A., Gibson R., Hadjigeorgiou G., Wolf J., Spector T. D., Segata N., Berry S. E.

المساهمون: Asnicar, F., Leeming, E. R., Dimidi, E., Mazidi, M., Franks, P. W., Al Khatib, H., Valdes, A. M., Davies, R., Bakker, E., Francis, L., Chan, A., Gibson, R., Hadjigeorgiou, G., Wolf, J., Spector, T. D., Segata, N., Berry, S. E.

مصطلحات موضوعية: gastrointestinal transit, intestinal bacteria

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33722860; info:eu-repo/semantics/altIdentifier/wos/WOS:000684206400011; volume:70; issue:9; firstpage:1665; lastpage:1674; numberofpages:10; journal:GUT; info:eu-repo/grantAgreement/EC/H2020/825410; http://hdl.handle.net/11572/322792Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85102698102; https://gut.bmj.com/content/70/9/1665.infoTest

الإتاحة: https://doi.org/10.1136/gutjnl-2020-323877Test
http://hdl.handle.net/11572/322792Test
https://gut.bmj.com/content/70/9/1665.infoTest

المؤلفون: Bolte, L. A., Lee, K. A., Björk, J. R., Leeming, E. R., Campmans-Kuijpers, M. J. E., de Haan, J. J., Vila, A. V., Maltez-Thomas, A., Segata, N., Board, R., Harries, M., Lorigan, Paul C, de Vries, E. G. E., Nathan, P., Fehrmann, R., Bataille, V., Spector, T. D., Hospers, G. A. P., Weersma, R. K.

المساهمون: Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands

العلاقة: https://dx.doi.org/10.1001/jamaoncol.2022.7753Test; Bolte LA, Lee KA, Björk JR, Leeming ER, Campmans-Kuijpers MJE, de Haan JJ, et al. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. JAMA Oncol. 2023 Feb 16. PubMed PMID: 36795408. Pubmed Central PMCID: PMC9936383 from the Seerave Foundation during the conduct of the study. Dr Leeming reported personal fees from Zoe Ltd outside the submitted work. Dr Campmans-Kuijpers reported grants from Seerave Foundation during the conduct of the study as well as personal fees from Takeda and Janssen outside the submitted work. Dr Segata reported grants from the Seerave Foundation during the conduct of the study as well as personal fees from Zoe outside the submitted work. Dr Board reported funding for conferences and paid speaker fees from BMS, MSD, and Novartis. Dr Lorigan reported personal fees from BMS, Merck, Novartis, GSK, Amgen, Chugai, PierreFabre, NeraCare, Roche, and OncologyEducationCanada outside the submitted work. Dr de Vries reported institutional financial support from NSABP, Daiichi Sankyo, and Crescendo Biologics; grants from Amgen, Genentech, Roche, CytomX, G1 Therapeutics, Bayer, Synthon, Regeneron, Crescendo Biologics, GE Healthcare, and AstraZeneca; and service as a member of the ESMO-MCBS working party, chair of the ESMO Cancer Medicines Working Group, cochair of the RECIST committee, and member of expert panel for selection of the Essential Medicine List for the World Health Organization outside the submitted work. Dr Spector reported being a founder of and shareholder in Zoe Ltd outside the submitted work. Dr Hospers reported grants from the Seerave Foundation during the conduct of the study as well as personal fees from Amgen, Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis, Sanofi, and Pierre Fabre and grants from Bristol Myers Squibb. Dr Weersma reported personal fees from Takeda Pharmaceuticals outside the submitted work. No other disclosures were reported. Epub 2023/02/17. eng.; http://hdl.handle.net/10541/626069Test; JAMA Oncology

الإتاحة: https://doi.org/10.1001/jamaoncol.2022.7753Test
http://hdl.handle.net/10541/626069Test

المؤلفون: Lee K. A., Thomas A. M., Bolte L. A., Bjork J. R., de Ruijter L. K., Armanini F., Asnicar F., Blanco-Miguez A., Board R., Calbet-Llopart N., Derosa L., Dhomen N., Brooks K., Harland M., Harries M., Leeming E. R., Lorigan P., Manghi P., Marais R., Newton-Bishop J., Nezi L., Pinto F., Potrony M., Puig S., Serra-Bellver P., Shaw H. M., Tamburini S., Valpione S., Vijay A., Waldron L., Zitvogel L., Zolfo M., de Vries E. G. E., Nathan P., Fehrmann R. S. N., Bataille V., Hospers G. A. P., Spector T. D., Weersma R. K., Segata N.

المساهمون: Lee, K. A., Thomas, A. M., Bolte, L. A., Bjork, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Leeming, E. R., Lorigan, P., Manghi, P., Marais, R., Newton-Bishop, J., Nezi, L., Pinto, F., Potrony, M., Puig, S., Serra-Bellver, P., Shaw, H. M., Tamburini, S., Valpione, S., Vijay, A., Waldron, L., Zitvogel, L., Zolfo, M., de Vries, E. G. E., Nathan, P., Fehrmann, R. S. N., Bataille, V., Hospers, G. A. P., Spector, T. D., Weersma, R. K., Segata, N.

مصطلحات موضوعية: Settore BIO/19 - Microbiologia Generale

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35228751; info:eu-repo/semantics/altIdentifier/wos/WOS:000762162700004; volume:28; issue:3; firstpage:535; lastpage:544; numberofpages:10; journal:NATURE MEDICINE; https://hdl.handle.net/10278/5008542Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85125299112

الإتاحة: https://doi.org/10.1038/s41591-022-01695-5Test
https://hdl.handle.net/10278/5008542Test

المؤلفون: Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., Derosa, L., Dhomen, N., Brooks, K., Harland, M., Harries, M., Leeming, E. R., Lorigan, P., Manghi, P., Marais, R., Newton-Bishop, J., Nezi, L., Pinto, F., Potrony, M., Puig, S., Serra-Bellver, P., Shaw, H. M., Tamburini, S., Valpione, S., Vijay, A., Waldron, L., Zitvogel, L., Zolfo, M., de Vries, E. G. E., Nathan, P., Fehrmann, R. S. N., Bataille, V., Hospers, G. A. P., Spector, T. D., Weersma, R. K., Segata, N.

المساهمون: Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. Department CIBIO, University of Trento, Trento, Italy. Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands. Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands. Department of Oncology, Lancashire Teaching Hospitals NHS Trust, Preston, UK. Dermatology Department, Hospital Clínic Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. U1015 INSERM, University Paris Saclay, Gustave Roussy Cancer Center and Oncobiome Network, Villejuif-Grand-Paris, France. Molecular Oncology Group, CRUK Manchester Institute, University of Manchester, Manchester, UK. Division of Haematology and Immunology, Institute of Medical Research at St. James's, University of Leeds, Leeds, UK. Biochemical and Molecular Genetics Department, Hospital Clínic de Barcelona, IDIBAPS and University of Barcelona, Barcelona, Spain. Department of Medical Oncology, Guys Cancer Centre, Guys and St Thomas's NHS Trust, London, UK. The Christie NHS Foundation Trust, Manchester, UK. Division of Cancer Sciences, University of Manchester, Manchester, UK. European Institute of Oncology (Istituto Europeo di Oncologia, IRCSS), Milan, Italy. Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK. Rheumatology & Orthopaedics Division, School of Medicine, University of Nottingham, Nottingham, UK. Graduate School of Public Health and Health Policy, City University of New York, New York, NY, USA. Department of Dermatology, Mount Vernon Cancer Centre, Northwood, UK. Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. tim.spector@kcl.ac.uk. Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands. r.k.weersma@umcg.nl. Department CIBIO, University of Trento, Trento, Italy. nicola.segata@unitn.it. European Institute of Oncology (Istituto Europeo di Oncologia, IRCSS), Milan, Italy. nicola.segata@unitn.it.

العلاقة: https://dx.doi.org/10.1038/s41591-022-01695-5Test; The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from five observational cohorts recruiting ICI-naive patients with advanced cutaneous melanoma (n = 165). Integrating the dataset with 147 metagenomic samples from previously published studies, we found that the gut microbiome has a relevant, but cohort-dependent, association with the response to ICIs. A machine learning analysis confirmed the link between the microbiome and overall response rates (ORRs) and progression-free survival (PFS) with ICIs but also revealed limited reproducibility of microbiome-based signatures across cohorts. Accordingly, a panel of species, including Bifidobacterium pseudocatenulatum, Roseburia spp. and Akkermansia muciniphila, associated with responders was identified, but no single species could be regarded as a fully consistent biomarker across studies. Overall, the role of the human gut microbiome in ICI response appears more complex than previously thought, extending beyond differing microbial species simply present or absent in responders and nonresponders. Future studies should adopt larger sample sizes and take into account the complex interplay of clinical factors with the gut microbiome over the treatment course.; http://hdl.handle.net/10541/625104Test; Nature Medicine

الإتاحة: https://doi.org/10.1038/s41591-022-01695-5Test
http://hdl.handle.net/10541/625104Test